J&J: Study Shows 'Real World Evidence' of Covid Vaccine's 'Durable Protection' Against Breakthrough Infection
January 06 2022 - 04:32PM
Dow Jones News
By Josh Beckerman
Johnson & Johnson said new study results provide "real world
evidence" that its Covid-19 vaccine "demonstrates durable
protection against breakthrough Infection, hospitalization, and
intensive care unit admission in the United States."
"While these are rapidly evolving data, we are seeing vaccine
effectiveness against COVID-19-related hospitalization of
approximately 80 percent from a single shot of the Johnson &
Johnson vaccine, and this level of protection holds steady across
the length of time studied thus far -- up to six months," the
company said.
J&J said the new study posted on medRxiv "comprehensively
looked at the durability profiles for all three vaccines authorized
or approved in the U.S. using the same methodology across three
outcomes of interest: COVID-19 breakthrough infections,
hospitalizations, and ICU admissions."
Last week, the company said its booster vaccine for Covid-19 was
85% effective against hospitalization in a study conducted in South
Africa after the Omicron variant became dominant.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 06, 2022 17:17 ET (22:17 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024